Triple-negative breast cancer (TNBC) presents a marked diversity at the molecular level, which promotes a clinical heterogeneity that further complicates treatment. We performed a detailed whole exome sequencing profile of 29 Mexican patients with long follow-up TNBC to identify genomic alterations associated with overall survival (OS), disease-free survival (DFS), and pathologic complete response (PCR), with the aim to define their role as molecular predictive factors of treatment response and prognosis. We detected 31 driver genes with pathogenic mutations in TP53 (53%), BRCA1/2 (27%), CDKN1B (9%), PIK3CA (9%), and PTEN (9%), and 16 operative mutational signatures. Moreover, tumors with mutations in BRCA1/2 showed a trend of sensitivity t...
Aim: Triple negative breast cancer (TNBC) is known as aggressive subtype and have no identified targ...
<div><p>Triple negative breast cancer (TNBC), defined by the lack of expression of the estrogen rece...
Whole-genome sequencing (WGS) brings comprehensive insights to cancer genome interpretation. To expl...
Triple-negative breast cancer (TNBC) presents a marked diversity at the molecular level, which promo...
Introduction<br/>In triple negative breast cancers (TNBC) the initial response to chemotherapy is of...
Abstract Triple negative breast cancer (TNBC) is a heterogeneous disease with aggressive behavior an...
Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10-15% are...
Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10-15% are...
Triple-negative breast cancer (TNBC) represents about 19% of all breast cancer cases in the Chinese ...
Triple-negative breast cancer (TNBC) is an aggressive form of breast carcinoma with a poor prognosis...
Abstract Triple Negative Breast Cancer (TNBC), negative for estrogen, progesterone and Her2 receptor...
Whole-genome sequencing (WGS) brings comprehensive insights to cancer genome interpretation. To expl...
Triple negative breast cancer (TNBC), defined by the lack of expression of the estrogen receptor, pr...
In triple-negative breast cancer (TNBC), only 30% of patients treated with neoadjuvant chemotherapy ...
Triple negative breast cancers (TNBCs) represent about 15–20% of all breast cancer cases and are cha...
Aim: Triple negative breast cancer (TNBC) is known as aggressive subtype and have no identified targ...
<div><p>Triple negative breast cancer (TNBC), defined by the lack of expression of the estrogen rece...
Whole-genome sequencing (WGS) brings comprehensive insights to cancer genome interpretation. To expl...
Triple-negative breast cancer (TNBC) presents a marked diversity at the molecular level, which promo...
Introduction<br/>In triple negative breast cancers (TNBC) the initial response to chemotherapy is of...
Abstract Triple negative breast cancer (TNBC) is a heterogeneous disease with aggressive behavior an...
Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10-15% are...
Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10-15% are...
Triple-negative breast cancer (TNBC) represents about 19% of all breast cancer cases in the Chinese ...
Triple-negative breast cancer (TNBC) is an aggressive form of breast carcinoma with a poor prognosis...
Abstract Triple Negative Breast Cancer (TNBC), negative for estrogen, progesterone and Her2 receptor...
Whole-genome sequencing (WGS) brings comprehensive insights to cancer genome interpretation. To expl...
Triple negative breast cancer (TNBC), defined by the lack of expression of the estrogen receptor, pr...
In triple-negative breast cancer (TNBC), only 30% of patients treated with neoadjuvant chemotherapy ...
Triple negative breast cancers (TNBCs) represent about 15–20% of all breast cancer cases and are cha...
Aim: Triple negative breast cancer (TNBC) is known as aggressive subtype and have no identified targ...
<div><p>Triple negative breast cancer (TNBC), defined by the lack of expression of the estrogen rece...
Whole-genome sequencing (WGS) brings comprehensive insights to cancer genome interpretation. To expl...